141 related articles for article (PubMed ID: 20147452)
1. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.
DiNitto JP; Deshmukh GD; Zhang Y; Jacques SL; Coli R; Worrall JW; Diehl W; English JM; Wu JC
J Biochem; 2010 Apr; 147(4):601-9. PubMed ID: 20147452
[TBL] [Abstract][Full Text] [Related]
2. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
Gajiwala KS; Wu JC; Christensen J; Deshmukh GD; Diehl W; DiNitto JP; English JM; Greig MJ; He YA; Jacques SL; Lunney EA; McTigue M; Molina D; Quenzer T; Wells PA; Yu X; Zhang Y; Zou A; Emmett MR; Marshall AG; Zhang HM; Demetri GD
Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1542-7. PubMed ID: 19164557
[TBL] [Abstract][Full Text] [Related]
3. Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.
Zhang HM; Yu X; Greig MJ; Gajiwala KS; Wu JC; Diehl W; Lunney EA; Emmett MR; Marshall AG
Protein Sci; 2010 Apr; 19(4):703-15. PubMed ID: 20095048
[TBL] [Abstract][Full Text] [Related]
4. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.
Laine E; Chauvot de Beauchêne I; Perahia D; Auclair C; Tchertanov L
PLoS Comput Biol; 2011 Jun; 7(6):e1002068. PubMed ID: 21698178
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit.
DiNitto JP; Wu JC
Crit Rev Biochem Mol Biol; 2011 Aug; 46(4):295-309. PubMed ID: 21539479
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation in the activation loop as the finishing touch in c-Kit activation.
Miyazawa K
J Biochem; 2012 May; 151(5):457-9. PubMed ID: 22437942
[TBL] [Abstract][Full Text] [Related]
8. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
Srikakulam SK; Bastys T; Kalinina OV
Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
[TBL] [Abstract][Full Text] [Related]
9. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Liao AT; Chien MB; Shenoy N; Mendel DB; McMahon G; Cherrington JM; London CA
Blood; 2002 Jul; 100(2):585-93. PubMed ID: 12091352
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
Mol CD; Dougan DR; Schneider TR; Skene RJ; Kraus ML; Scheibe DN; Snell GP; Zou H; Sang BC; Wilson KP
J Biol Chem; 2004 Jul; 279(30):31655-63. PubMed ID: 15123710
[TBL] [Abstract][Full Text] [Related]
14. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
15. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Kitagawa D; Gouda M; Kirii Y; Sugiyama N; Ishihama Y; Fujii I; Narumi Y; Akita K; Yokota K
J Biochem; 2012 Jan; 151(1):47-55. PubMed ID: 21880693
[TBL] [Abstract][Full Text] [Related]
16. Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight.
Purohit R
J Biomol Struct Dyn; 2014; 32(7):1033-46. PubMed ID: 23782055
[TBL] [Abstract][Full Text] [Related]
17. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
18. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
Judson IR
J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449
[No Abstract] [Full Text] [Related]
19. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.
Fernández A; Sanguino A; Peng Z; Crespo A; Ozturk E; Zhang X; Wang S; Bornmann W; Lopez-Berestein G
Cancer Res; 2007 May; 67(9):4028-33. PubMed ID: 17483313
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
